Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
November 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc....
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
June 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
November 21, 2023 07:45 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...